STDR 2022 (Sep) Events

Launch of 2022 (Sep) Grant Call

The STDR grant call is open for submission of Full Proposal applications for the Pre-Pilot Streams 1 & 2 from 12 September 2022 to 27 October 2022, 5pm.

STDR 2022 (Sep) Roadshow

The 2022 (Sep) STDR roadshow was held on 8 September 2022 and featured an introduction to the STDR grant call, a talk on the attributes of a strong STDR application, a presentation on Intellectual Property (IP) in therapeutics research and 1-1 consultation sessions with STDR secretariat and our strategic partners EDDC and SMART (who administer the Pre-Pilot Stream 1 and 2 respectively). The STDR roadshow deck can be downloaded below.

STDR 2022 (Sep) Roadshow deck

About the Grant

The Singapore Therapeutics Development Review (STDR) is a national-level grant call implemented by the Agency for Science, Technology and Research (A*STAR) in partnership with our strategic partners, the Experimental Drug Development Centre (EDDC), Singapore-MIT Alliance for Research and Technology (SMART) and National Health Innovation Centre (NHIC).

STDR aims to boost the quality and quantity of drug development and biotech pipelines in Singapore through 2 key features:
1. Phased funding support to potential high-value drug discovery and development projects from the local research community, based on the maturity and industry-readiness of projects; and
2. Mentoring from leading entrepreneurs, innovators and/or venture capitalists, and training through bootcamps, workshops and/or seminars, to provide dedicated guidance and upskilling opportunities to grant awardees.


The STDR (Pilot) is typically called twice a year, in April and September. The STDR (Pre-Pilot) is called once a year, typically in September. It is highly encouraged but optional to have a clinical Co-Investigator or collaborator.

The Pre-Pilot stage aims to support earlier-stage and more exploratory, proof-of-concept projects that have some preliminary data. Stream 1 (Target Validation) will support single target/single asset projects and will be facilitated by EDDC as a continuation of the Target Translation Consortium (TTC)1 scheme from RIE2020. Stream 2 (Platform Development) will support platform discovery projects and will be facilitated by SMART.

Applicants may refer to the guide in Information Sheet Annex A to determine which grant type is most suitable for your project.

Note: We will not be launching the STDR (Pilot) for the 2022 (Sep) grant call. Instead we will organise a workshop tentatively in November 2022 to give researchers guidance to better prepare them for the STDR grant application. More details on the workshop will be shared later. The next grant call for the Pilot projects will tentatively be held in early CY2023.

1 The Target Translation Consortium (TTC) had previously launched an annual “Call for Targets” in 2019 and 2020. From 2021, this Call was integrated with the STDR, and the TTC now provides its support for the preclinical validation of promising, putative drug targets through this Pre-Pilot Stream 1 programme instead.  

Thematic Area

STDR will fund therapeutic projects in small molecules, large molecules, cell and gene therapies and platform technologies. 

Funding Principles

Up to S$100k per project (including 30% indirect costs) over a maximum of 1 year.

Selection of successful proposals would be based on the following evaluation criteria:

  • Scientific excellence
  • Potential for scientific breakthroughs / Disruptive innovation
  • Unmet medical need to be addressed
  • Competition and potential / Current market size
  • Potential impact / Relevance to Singapore
  • Credibility of team
Applicants may refer to the Information Sheet Annex B for the detailed evaluation criteria for the Pre-Pilot (Streams 1 & 2) and Pilot stages.

Eligibility Criteria

Applicants are required to fulfill the following criteria at the point of application:

The Lead Principal Investigator (PI) should:

  • Hold at least a 0.7 FTE primary appointment in a Singapore publicly funded research or tertiary institution;
  • Have the relevant scientific/technical background and necessary experience to direct the project being supported by the grant2
Exceptions to eligibility criteria will be considered on a case-by-case basis with the submission of a waiver request. Please write to the grant secretariat at least one week before the submission of your application.

Post-doctoral researchers who wish to apply for STDR should submit a letter from their supervisor declaring that (a) the supervisor supports the post-doctoral researcher's STDR application, (b) the contract of the post-doctoral researcher covers the entire STDR grant period, and (c) the grant body that is funding the post-doctoral researcher is agreeable to their application for STDR grants (if relevant).

Grant Call Timeline
Stage 1: Submission of Full Proposals
Launch of Call for Full Proposal12 September 2022 
Deadline for Submission of Full Proposals on iGrants 27 October 2022, 5pm
Presentation to Review Panel* (for Stream 2 only)  TBC
Award End March 2023

Applicants for Pre-Pilot Stream 2 must ensure they are available to the meeting marked (*) above.

Application Procedure

Applicants are required to submit their applications via the iGrants website: by 27 October 2022, 5pm (Singapore time)

Please submit your application to the “Singapore Therapeutics Development Review 2022 (Sep) Pre-Pilot” grant call. Only complete applications submitted on iGrants by the deadline will be accepted. Applicants are advised to submit their applications early in the event of technical errors with the iGrants website.

Applications must be fully endorsed by the applicant, applicants’ respective Industry and Enterprise Offices (IEOs) and Directors of Research (DORs). Applicants are strongly encouraged to approach their respective IEO representatives and DORs early to give sufficient time to gather input and endorsement.

More details on the grant application steps using iGrants can be found in the Information Sheet Annex C

For Enquiries

General Enquiries:
Dr Tan Yun Xuan (A*STAR) 
Dr Siti Munirah (A*STAR)

Stream 1 (Target Validation): 

Stream 2 (Platform Development):
Dr Howard Califano (SMART)
Mr Brian Yen (SMART)